Unknown OBSERVATIONAL NCT05544123

The Treatment Situation of Chinese County Population With Breast Cancer

A Multi-center, Observational Study to Describe the Treatment Situation of Chinese County Population With HER2+ & HR+/HER2- Breast Cancer

Sponsor: AstraZeneca

Conditions Breast Cancer Breast Carcinoma Breast Tumor

Interventions pathological stage

Updated 5 times since 2022 Last updated: Jan 1, 2023 Started: Sep 29, 2022 Primary completion: Aug 31, 2023 Completion: Sep 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Breast Cancer and Breast Carcinoma and is currently ongoing. AstraZeneca leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Feb 2025 — Present [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Feb 2023 — Jul 2024 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Feb 2023 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
The First Affiliated Hospital of Xinxiang Medical College

Data source: The First Affiliated Hospital of Xinxiang Medical College

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xinxiang, China